Outsourced services providers stand to benefit in the pharmaceutical value chain as China’s drug development sector is awash with funding. Photo: AFP Outsourced services providers stand to benefit in the pharmaceutical value chain as China’s drug development sector is awash with funding. Photo: AFP
Outsourced services providers stand to benefit in the pharmaceutical value chain as China’s drug development sector is awash with funding. Photo: AFP

Mergers afoot for China’s biotechnology industry as suppliers become attractive targets for Big Pharma

  • Outsourced drug discovery services providers stand to benefit from industry boom, regardless of whether drug development efforts succeed or not
  • Industry is benefiting from abundant funding from private equity firms and stock market offerings, Advent International says

Topic |   Pharmaceuticals
Outsourced services providers stand to benefit in the pharmaceutical value chain as China’s drug development sector is awash with funding. Photo: AFP Outsourced services providers stand to benefit in the pharmaceutical value chain as China’s drug development sector is awash with funding. Photo: AFP
Outsourced services providers stand to benefit in the pharmaceutical value chain as China’s drug development sector is awash with funding. Photo: AFP

Corrected [5:34pm, 29 Sep, 2020]

  • [5:34pm, 29 Sep, 2020]

    Corrects the name of merged entity in the sixth paragraph

  • We are part of the Trust Project What is it?
READ FULL ARTICLE